Research programme: eye disorders therapeutics controlled release - Ohr Pharmaceutical

Drug Profile

Research programme: eye disorders therapeutics controlled release - Ohr Pharmaceutical

Alternative Names: OHR-3031

Latest Information Update: 11 Aug 2016

Price : $50

At a glance

  • Originator Ohr Pharmaceutical
  • Class Proteins; Small molecules
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Allergic conjunctivitis; Glaucoma; Open-angle glaucoma; Retinal disorders

Most Recent Events

  • 09 Aug 2016 Pharmacodynamics data from a preclinical trial in Allergic conjunctivitis released by OHR
  • 17 Dec 2015 Ohr Pharmaceuticals has patent-protection for SKS sustained release technology
  • 03 Dec 2015 Preclinical trials in Retinal disorders, Open angle glaucoma, Glaucoma, Allergic conjunctivitis in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top